Baseline demographics and characteristics
| ITT | MEP | KRAS-WT* | mKRAS | mTP53 | mKEAP1 | mSTK11 | |||||||||
| ACP | ABCP | BCP | ACP | ABCP | BCP | ACP | ABCP | BCP | ACP | ABCP | BCP | ||||
| N | 1047 | 920 | 695 | 74 | 80 | 71 | 125 | 129 | 127 | 46 | 57 | 40 | 50 | 46 | 37 |
| Race, n (%) | |||||||||||||||
| Asian | 93 (8.9) | 86 (9.4) | 72 (10.4) | 7 (9.5) | 6 (7.5) | 1 (1.4) | 11 (8.8) | 17 (13.2) | 10 (7.9) | 3 (6.5) | 7 (12.3) | 1 (2.5) | 1 (2.0) | 5 (10.9) | 1 (2.7) |
| White | 894 (85.4) | 780 (84.8) | 584 (84.0) | 64 (86.5) | 68 (85.0) | 64 (90.1) | 105 (84.0) | 107 (83.0) | 109 (85.8) | 42 (91.3) | 49 (86.0) | 35 (87.5) | 46 (92.0) | 38 (82.6) | 32 (86.5) |
| Median age (range), years | 63 (31–89) | 63 (31–89) | 63 (31–89) | 63.5 (38–85) | 65.5 (43–81) | 62 (42–83) | 62 (32–82) | 63 (31–79) | 63 (41–87) | 65 (48–85) | 62 (43–81) | 62 (43–82) | 65.5 (38–85) | 62 (46–77) | 60 (41–82) |
| Male, n (%) | 649 (62.0) | 575 (62.5) | 440 (63.3) | 41 (55.4) | 50 (62.5) | 44 (62.0) | 81 (64.8) | 91 (70.5) | 84 (66.1) | 33 (71.7) | 45 (79.0) | 29 (72.5) | 31 (62.0) | 32 (69.6) | 25 (67.6) |
| Female, n (%) | 398 (38.0) | 345 (37.5) | 255 (36.7) | 33 (44.6) | 30 (37.5) | 27 (38.0) | 44 (35.2) | 38 (29.5) | 43 (33.9) | 13 (28.3) | 12 (21.1) | 11 (27.5) | 19 (38.0) | 14 (30.4) | 12 (32.4) |
| ECOG PS, n (%)† | |||||||||||||||
| 0 | 439 (42.2) | 392 (42.8) | 311 (45.0) | 29 (39.2) | 26 (32.9) | 26 (36.6) | 52 (41.6) | 44 (34.7) | 45 (36.0) | 15 (32.6) | 15 (26.8) | 14 (35.0) | 16 (32.0) | 16 (34.8) | 12 (33.3) |
| 1 | 602 (57.8) | 523 (57.2) | 380 (55.0) | 45 (60.8) | 53 (67.1) | 45 (63.4) | 73 (58.4) | 83 (65.4) | 80 (64.0) | 31 (67.4) | 41 (73.2) | 26 (65.0) | 34 (68.0) | 30 (65.2) | 24 (66.7) |
| Smoking history, n (%) | |||||||||||||||
| Never smoker | 154 (14.7) | 134 (14.6) | 126 (18.1) | 3 (4.1) | 2 (2.5) | 3 (4.2) | 14 (11.2) | 17 (13.2) | 9 (7.1) | 2 (4.3) | 1 (1.8) | 0 (0) | 2 (4.0) | 2 (4.3) | 0 (0) |
| Current/ previous smoker | 893 (85.3) | 786 (85.4) | 569 (81.9) | 71 (95.9) | 78 (97.5) | 68 (95.8) | 111 (88.8) | 112 (86.8) | 118 (92.9) | 44 (95.7) | 56 (98.2) | 40 (100) | 48 (96.0) | 44 (95.7) | 37 (100) |
| Liver metastasis, n (%) | 135 (12.9) | 122 (13.3) | 82 (11.8) | 11 (14.9) | 10 (12.5) | 19 (26.8) | 22 (17.6) | 28 (21.7) | 32 (25.2) | 9 (19.6) | 8 (14.0) | 12 (30.0) | 9 (18.0) | 7 (15.2) | 9 (24.3) |
| Baseline SLD, median, mm | 73.0 | 74.0 | 71.0 | 90.0 | 83.0 | 90.0 | 90.0 | 86.4 | 90.0 | 97.8 | 90.0 | 91.5 | 95.8 | 97.0 | 109.0 |
| CRP, median, mg/L | 13.9 | 14.8 | 10.3 | 30.8 | 22.2 | 35.2 | 20.9 | 21.7 | 26.9 | 43.7 | 36.1 | 33.8 | 44.8 | 40.1 | 32.1 |
*Refers to patients with KRAS-WT tumors.
†N=1041; 6 ITT patients had missing ECOG values.
ABCP, atezolizumab plus bevacizumab plus carboplatin/paclitaxel; ACP, atezolizumab plus carboplatin/paclitaxel; BCP, bevacizumab plus carboplatin/paclitaxel; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; ITT, intention-to-treat; KRAS-WT, Kirsten rat sarcoma viral oncogene homolog wild type; MEP, mutation-evaluable population; mKEAP1, mutation in kelch-like ECH associated protein 1; mKRAS, mutation in the Kirsten rat sarcoma viral oncogene homolog; mSTK11, mutations in serine/threonine kinase 11; mTP53, mutation in tumor protein 53; SLD, sum of longest diameter of target lesion; WT, wild-type.